Skip to content

Translation, Cross-cultural Adaptation and Validation of PRO-CTCAE for Italian-speaking Cancer Patients

Translation, Cross-Cultural Adaptation and Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) for Italian-speaking Cancer Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02381054
Acronym
PRO-CTCAE
Enrollment
233
Registered
2015-03-06
Start date
2015-05-31
Completion date
2017-06-22
Last updated
2017-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Patient reported outcomes

Brief summary

The purpose of this study is to see if the Italian language version of a questionnaire about symptoms that patients may have during cancer treatment is understandable to Italian speaking patients. The questionnaire is called the PRO-CTCAE, and was originally developed at the U.S. National Cancer Institute to help get information about patients' symptoms directly from the patients themselves. The Italian version of the questionnaire will be used in future studies to gain a better understanding of patient symptoms.

Detailed description

This study will be conducted in two steps. The first is the Italian translation and cross cultural adaptation of the original US NCI's version of the PRO-CTCAE questionnaire. The questionnaire will be translated and administered to a sample of 96 Italian patients. After protocol amendment in November 2016, the second step was modified and consists of test-retest reliability assessment of the Italian language version of the PRO-CTCAE questionnaire that was developed in the first step, with a minimum of 59 Italian speaking patients to be enrolled. A validation study is planned and will be the subject of a separate protocol.

Interventions

None listed

Sponsors

National Cancer Institute, Naples
CollaboratorOTHER
F.A.V.O. Italian Federation of Volunteer-Based Cancer Organizations
CollaboratorUNKNOWN
SmithKline Foundation
CollaboratorUNKNOWN
Parma University Hospital
CollaboratorOTHER
IRCCS AOU San Martino -IST Genoa
CollaboratorUNKNOWN
Istituti Ospitalieri di Cremona
CollaboratorOTHER
Fondazione IRCCS Policlinico San Matteo di Pavia
CollaboratorOTHER
Italian PRO-CTCAE Study Group
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Eligibility Criteria for cross-cultural adaption phase: Inclusion criteria: * patients receiving (or who have received within 6 months) chemotherapy or radiotherapy with curative or palliative intent for an advanced cancer at one of the study sites * ≥18 years of age * able to speak and understand Italian * providing written informed consent

Exclusion criteria

• Patients judged unable to report on their symptoms from the last seven days due to cognitive impairment. Eligibility Criteria for Validation phase: Inclusion Criteria: * ≥18 years of age. * Patient is able to complete PRO-CTCAE on two consecutive days. * Patient is actively receivingmedical treatment for cancer or has completed treatment not more than 4 weeks before Visit 1 * Any type of cancer * Able to complete questionnaire by themselves or with assistance. * Providing informed written consent. * Able to speak and understand Italian

Design outcomes

Primary

MeasureTime frame
cultural and linguistic validity of Italian language version of the PRO-CTCAE2 years

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026